TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01297452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120 days 1 - 21 plus paclitaxel + carboplatin
Description: Patients will receive oral daily BKM120 (days 1 - 21, per dose escalation scheme) plus paclitaxel (175 mg/m2 intravenously, day 1) + carboplatin (AUC 5 intravenously, day 1)on a 21-day cycle. Pegfilgrastim (6 mg/subcutaneously) will be administered on day 2 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120 (days 1 - 28, ) plus paclitaxel + carboplatin
Description: Patients will receive oral daily BKM120 (days 1 - 28, per dose escalation scheme) plus paclitaxel (80 mg/m2 intravenously, days 1, 8 and 15) + carboplatin (AUC 5 intravenously, day 1) on a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120 (days 1 - 28, ) plus paclitaxel + carboplatin
Description: Patients will receive oral daily BKM120 (days 1 - 28, per dose escalation scheme) plus paclitaxel (80 mg/m2 intravenously, days 1, 8 and 15) + carboplatin (AUC 5 intravenously, day 1) on a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120 (days 1-21) + paclitaxel (day 1) + carboplatin (day 1)
Description: BKM120 100 mg (days 1 - 21, per dose escalation scheme) plus paclitaxel (200 mg/m2 intravenously, day 1) + carboplatin (AUC 6 intravenously, day 1) on a 21-day cycle. After enrollment to Groups 1 and 2 has been completed and all patients in Group 1 and 2 have completed the DLT monitoring period, up to 6 additional patients will be enrolled in this EXPANSION COHORT.A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120, Paclitaxel + Carboplatin
Description: BKM120 100 mg per oral, days 1 - 21 Paclitaxel (175 mg/m2) intravenously on Day 1 Carboplatin (AUC 5) intravenously on Day 1 EXPANSION COHORT B
Study: NCT04127578

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3884961
Description: Participants will receive a single dose of LY3884961, administered intra-cisterna magna

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3884961
Description: Participants will receive a single dose of LY3884961, administered intra-cisterna magna

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 6 IV pulses administered as concomitant medication over 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 6 IV pulses administered as concomitant medication over 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Back-up treatment if corticosteroid is not well tolerated. Loading dose, followed by maintenance dose, followed by dose tapering; administered as concomitant medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Back-up treatment if corticosteroid is not well tolerated. Loading dose, followed by maintenance dose, followed by dose tapering; administered as concomitant medication
Study: NCT03212183

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EPI-TAVIE
Description: ÉPI-TAVIE is a web-based intervention focusing on epilepsy self-management. This interactive session (25 minutes) is facilitated by a virtual nurse.

Intervention type: OTHER
Group type: OTHER
Intervention: Websites
Description: The conventional websites offers reliable information about epilepsy. Their content were validated by experts.
Study: NCT04090216

Intervention type: DEVICE
Intervention: Primary Percutaneous Coronary Intervention
Description: Primary PCI will be done for patients with STEMI in both groups of patients

Intervention type: DEVICE
Intervention: Primary Percutaneous Coronary Intervention
Description: Primary PCI will be done for patients with STEMI in both groups of patients
Study: NCT00727259

Intervention type: BIOLOGICAL
Intervention: Peginterferon alfa-2b (SCH 54031)
Description: Peginterferon alfa-2b will be administered according to the products' labeling.
Study: NCT01511718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron Hydrochloride
Description: Ondansetron Hydrochloride Tablets 8 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron Hydrochloride
Description: Zofran Tablets 8 mg
Study: NCT00197002

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK Biologicals 2-dose inactivated hepatitis A vaccine (Havrix)
Description: Two doses, administered intramuscularly in the right anterolateral thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals 2-dose inactivated hepatitis A vaccine (Havrix)
Description: Two doses, administered intramuscularly in the right anterolateral thigh.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK Biologicals 2-dose inactivated hepatitis A vaccine (Havrix)
Description: Two doses, administered intramuscularly in the right anterolateral thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar™
Description: One dose, administered intramuscularly in the left anterolateral thigh.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar™
Description: One dose, administered intramuscularly in the left anterolateral thigh.
Study: NCT03698968

Intervention type: DEVICE
Group type: OTHER
Intervention: Negative Pressure Wound Therapy
Description: Single use disposable negative pressure system. The system is capable of delivering up to 80 mm Hg negative pressure to a wound or surgical incision site and managing low to moderate levels of exudate or fluid generated by the wound or incision. The therapy may be administered for up to 1 week.
Study: NCT00616603

Intervention type: DRUG
Group type: OTHER
Intervention: Ropivacaine
Description: 20 ml of 0.2% ropivacaine injected locally as regional anesthesia given once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 20 ml of 0.2% ropivacaine injected locally as regional anesthesia given once.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 20 ml of 0.2% ropivacaine injected locally as regional anesthesia given once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 8mg Dexamethasone injected locally along with ropivacaine for regional anesthesia given once.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 2ml(8mg)Dexamethasone given once intravenously.

Intervention type: DRUG
Group type: OTHER
Intervention: Normal Saline
Description: 2ml of normal saline given once intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: 2ml of normal saline given once intravenously.
Study: NCT00585715

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1064 nm Nd:YAG laser
Description: 3 treatments at 3-5 week intervals Spot size: 10 - 18 mm diameter Fluence: 50 J/cm2 Laser pulse duration: 50 ms Rep. rate: Up to 2 Hz DCD cooling 0-50 ms

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1064 nm Nd:YAG laser
Description: 3 treatments at 3-5 week intervals Spot size: 10 - 18 mm diameter Fluence: 50 J/cm2 Laser pulse duration: 50 ms Rep. rate: Up to 2 Hz DCD cooling 0-50 ms
Study: NCT01255462

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LFG316

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LFG316

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LFG316

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LFG316
Study: NCT03176615

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental diet
Description: The intervention will run concurrently with the gastric bypass treatment at the hospital. The first intervention is carried out before weight loss, and the intervention is repeated two times concurrently with two periods of weight loss (lifestyle and gastric bypass)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental diet
Description: The intervention will run concurrently with the gastric bypass treatment at the hospital. The first intervention is carried out before weight loss, and the intervention is repeated two times concurrently with two periods of weight loss (lifestyle and gastric bypass)
Study: NCT01968356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3M CHG/IPA Prep Colorless
Description: Apply topically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3M CHG/IPA Prep Tint
Description: Apply topically.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ChloraPrep
Description: Apply topically.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Apply topically.
Study: NCT01093326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponesimod 10 mg
Description: Ponesimod 10 mg oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponesimod 20 mg
Description: Ponesimod 20 mg oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponesimod 40 mg
Description: Ponesimod 40 mg oral use
Study: NCT01060878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PYM50028
Description: IMP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PYM50028
Description: IMP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PYM50028
Description: IMP

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo comprising identical vehicle to active doses
Study: NCT01658592

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Stimulator setting is ON

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Deep brain stimulation
Description: Stimulator setting is ON
Study: NCT00993317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP870 200mg
Description: 400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2 weeks until Week 22(SC)
Study: NCT00727259

Intervention type: DRUG
Intervention: Ribavirin (SCH 18908)
Description: Ribavirin will be administered according to the products' labeling.
Study: NCT02540343

Intervention type: OTHER
Intervention: questionnaires
Description: fill out all questionnaires twice

Intervention type: OTHER
Intervention: questionnaires
Description: fill out all questionnaires twice

Intervention type: OTHER
Intervention: questionnaires
Description: fill out all questionnaires twice
Study: NCT00038961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fondaparinux sodium
Description: 2.5 mg fondparinux sodium, daily, s.c. starting 6 to 8 hours after surgical closure for up to 7 +/- 2 days, administered on top of IPC +/- elastic stockings (ES)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, daily, s.c. starting 6 to 8 hours after surgical closure for up to 7 +/- 2 days, administered on top of IPC +/- elastic stockings (ES)
Study: NCT02368366

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist Guided Face to Face Family Problem Solving
Description: Families assigned to this arm will meet with the therapist in person at the medical center TBI clinic. Sessions will last approximately 60 minutes and cover didactic content using printed handouts provided as part of a family workbook.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist Guided Online Family Problem Solving
Description: Families assigned to this arm will receive a password enabling them to access the online intervention materials throughout the course of the intervention. Each session of online F-PST consists of a self-guided online portion providing didactic content regarding the desired skill (i.e., problem-solving), video clips showing individuals and families modeling the skill, and exercises and assignments giving the family an opportunity to practice the skill. During synchronous, videoconference sessions with the therapist, the family will review the online materials and practice the problem-solving process.
Study: NCT01658592

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Stimulator setting is ON

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Stimulator setting is ON
Study: NCT02368366

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Guided Online Family Problem Solving
Description: Families in the self-guided, online F-PST arm will receive a password enabling them to access the online intervention materials throughout the course of the intervention. They will receive access to the same web-modules as the therapist-guided group, but will review them on their own without therapist support. Participants in this group will be encouraged to complete web modules at the same schedule as participants in the other groups. If the family fails to log on or complete web modules, they will receive reminders via phone, text, or e-mail.
Study: NCT05213117

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Co-Localization with Nursing
Description: Co-localize 15 residents to one of 6 general medical floors to complete all 8 weeks of general medicine on this floor
Study: NCT01399502

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mood Memo emails
Description: Participants will receive 12 emails over 6 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mood Memo emails
Description: Participants will receive 12 emails over 6 weeks.
Study: NCT04013932

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KUPAA Intervention Group (Culturally Tailored Family Psychoeducation)
Description: KUPAA is composed of 3 key components:~1-2 Joining sessions \[\~30 to 45 minutes each\] give the facilitator and participants a chance to get to know each other before KUPAA groups begin and allows time for questions.~Educational Workshop is an interactive, one day workshop offering information about biological, psychological and social aspects of mental illness; the nature, effects and side effects of psychiatric treatments; what families can do to help recovery and prevent relapse; and guidelines for managing mental illnesses.~12 Family psychoeducation group sessions \[\~1.5 hours each session\] occur weekly in multi-family groups. These sessions follow an empirically tested format and focus on solving problems that interfere with treatment, illness, and symptoms management and that support coping skills and personal care. Case management may also be provided.
Study: NCT00514813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dynepo
Description: Subcutaneous injection either BIW, QW, Q2W or Q4W based on what is appropriate for the subject
Study: NCT02885883

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI 3T

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI 3T

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI 3T
Study: NCT01201915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Vismodegib was supplied in gelatin capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Vismodegib was supplied in gelatin capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Vismodegib was supplied in gelatin capsules.
Study: NCT06052683

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Low-Dose Rate Brachytherapy to the prostate using Iodine-125 seed implant
Description: Low-dose rate brachytherapy with Iodine-125 to a total dose of 144 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy to the prostate
Description: Prostate Stereotactic Body Radiation Therapy using 36.25 Gy in 5 fractions
Study: NCT00655369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0200390
Description: oral 15 mg daily dose, 3 capsules per dose during a six week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0200390
Description: oral 25 mg daily dose, 3 capsules per dose during a six week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0200390
Description: oral 35 mg daily dose, 3 capsules per dose during a six week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0200390
Description: oral 5 mg daily dose, 3 capsules per dose during a six week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0200390
Description: oral 50 mg daily dose, 3 capsules per dose during a six week treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral placebo daily dose, 3 capsules per dose during a six week treatment period.
Study: NCT01658592

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Stimulator setting is OFF

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Stimulator setting is OFF

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Stimulator setting is OFF

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Stimulator setting is OFF
Study: NCT02521779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-fat Treatment Meal
Description: Isocaloric test meal that provided 20% fat.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saturated-fat Treatment Meal
Description: Isocaloric test meal that provided 35% fat with saturated fat (16 g).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: N-3 fat Treatment Meal
Description: Isocaloric test meal that provided 35% fat with n-3 (DHA = 500mg)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: N-6 fat Treatment Meal
Description: Isocaloric test meal that provided 35% fat with n-6 (7.4 g).
Study: NCT04324736

Intervention type: OTHER
Intervention: no interventional study
Description: no interventional study

Intervention type: OTHER
Intervention: no interventional study
Description: no interventional study
Study: NCT03266692

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACTR087
Description: Autologous T cell product

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SEA-BCMA
Description: B-cell maturation antigen (BCMA)-directed antibody
Study: NCT02619396

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combination 1 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall
Description: 20 W RF power and target LSI = 4 on LA posterior wall

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combination 2 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall
Description: 40 W RF power and target LSI = 4 on LA posterior wall

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combination 3 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall
Description: 20 W RF power and target LSI = 5 on LA posterior wall

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combination 4 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall
Description: 40 W RF power and target LSI = 5 on LA posterior wall
Study: NCT04787796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a 28-channel ECG (MECG) system
Description: To test if a 28-channel ECG (MECG) system would efficiently differentiate the patients suspected to have CAD or ACS with acceptable sensitivity and specificity, and optimize this portable self-built-in multichannel ECG recorder system with various algorithms.
Study: NCT03257878

Intervention type: OTHER
Intervention: validated Korean version of the SF36 and EQ-5D
Description: This is an observational prospective study. SF36 consists of 36 questions that measure patient's HRQoL in 8 domains: physical functioning (PF), role-physical (RP), bodily pain (BP), general health (GH) that represent the physical HRQoL, vitality (VT), social functioning (SF), role-emotional (RE), and mental health (MH) that represent the mental HRQoL. Each domain is scored from 0 (worst health status) to 100 (best health status). The scores of these domains are summarized into the physical component score (PCS) and mental component score (MCS).~The EQ-5D questionnaire is made up for 2 components; health state description and evaluation. In description part, health status is measured in terms of 5 dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. In evaluation part, the respondents evaluate their overall health status using the visual analogue scale (EQ-VAS).

Intervention type: OTHER
Intervention: validated Korean version of the SF36 and EQ-5D
Description: This is an observational prospective study. SF36 consists of 36 questions that measure patient's HRQoL in 8 domains: physical functioning (PF), role-physical (RP), bodily pain (BP), general health (GH) that represent the physical HRQoL, vitality (VT), social functioning (SF), role-emotional (RE), and mental health (MH) that represent the mental HRQoL. Each domain is scored from 0 (worst health status) to 100 (best health status). The scores of these domains are summarized into the physical component score (PCS) and mental component score (MCS).~The EQ-5D questionnaire is made up for 2 components; health state description and evaluation. In description part, health status is measured in terms of 5 dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. In evaluation part, the respondents evaluate their overall health status using the visual analogue scale (EQ-VAS).

Intervention type: OTHER
Intervention: validated Korean version of the SF36 and EQ-5D
Description: This is an observational prospective study. SF36 consists of 36 questions that measure patient's HRQoL in 8 domains: physical functioning (PF), role-physical (RP), bodily pain (BP), general health (GH) that represent the physical HRQoL, vitality (VT), social functioning (SF), role-emotional (RE), and mental health (MH) that represent the mental HRQoL. Each domain is scored from 0 (worst health status) to 100 (best health status). The scores of these domains are summarized into the physical component score (PCS) and mental component score (MCS).~The EQ-5D questionnaire is made up for 2 components; health state description and evaluation. In description part, health status is measured in terms of 5 dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. In evaluation part, the respondents evaluate their overall health status using the visual analogue scale (EQ-VAS).
Study: NCT00993317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Received treatment with Methotrexate(MTX)for at least 24 weeks prior to the Baseline Visit.~The dose and route of administration of MTX had to have been stable for at least 8 weeks prior to the Baseline Visit. The minimum stable dose of MTX allowed is 10mg weekly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Received treatment with Methotrexate(MTX)for at least 24 weeks prior to the Baseline Visit.~The dose and route of administration of MTX had to have been stable for at least 8 weeks prior to the Baseline Visit. The minimum stable dose of MTX allowed is 10mg weekly.